Linked Life Data

18782794

Source:http://linkedlifedata.com/resource/pubmed/id/18782794

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2009-8-13
pubmed:abstractText
The safety and potential efficacy of a chimaeric anti-tumour necrosis factor alpha monoclonal antibody (infliximab) were examined in diffuse cutaneous systemic sclerosis (dcSSc).
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1468-2060
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
68
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1433-9
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
An open-label pilot study of infliximab therapy in diffuse cutaneous systemic sclerosis.
pubmed:affiliation
Centre for Rheumatology, Royal Free Hospital, Pond Street, London NW3 2QG, UK. c.denton@medsch.ucl.ac.uk
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't